Opinions of French patients with schizophrenia regarding injectable medication by Caroli, François et al.
© 2011 Caroli et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Patient Preference and Adherence 2011:5 165–171
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
165
OriginAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/PPA.S15337
Opinions of French patients with schizophrenia 
regarding injectable medication
François Caroli1 
Philippe raymondet2 
isabelle izard3 
Joel Plas4 
Bérengère gall5 
Antonio Delgado6
1Psychiatry Department, Centre 
hospitalier sainte-Anne, Paris, 
France; 2Psychiatry Department, CMP 
Chalucet, Toulon, France; 3Psychiatry 
Department, CMP Jean Wier, suresnes, 
France; 4Psychiatry Department, Ch 
Jean Charcot, Vélizy, France; 5Opinion 
and health Department, BVA group, 
Boulogne-Billancourt, France; 
6neurosciences Department, Janssen 
Cilag France, issy-les-Moulineaux, 
France
Correspondence: François Caroli 
Psychiatry Department, Centre 
hospitalier sainte-Anne, 1 rue Cabanis, 
75674 Paris Cedex, France 
Tel +33 145 658 309 
Fax +33 145 658 740 
email f.caroli@ch-sainte-anne.fr
Background: Use of patient-reported outcomes to assess the care of individuals with 
schizophrenia is increasing. We describe a survey (questionnaire) that evaluates patient opinions 
on long-acting injectable antipsychotic medication.
Methods: Psychiatrists throughout France selected consenting patients with schizophrenia who 
had received at least three months’ treatment with a long-acting injectable antipsychotic (either 
typical or atypical) as outpatients to be interviewed by professional interviewers.
Results: A total of 206 patients were interviewed at 19 sites. Ninety-five percent of the patients 
had been treated with more than one form of dosage; for these individuals, injections were the 
favored dosage form, being preferred by 47% (compared with 35%, 7%, and 1% expressing a 
preference for oral tablets, drinkable solutions, and orally disintegrating tablets, respectively, 
whilst 10% of patients did not express a preference). Over two-thirds of the interviewees (67%) 
said they felt better having received an injectable treatment than they felt before, and over half 
the patients (51%) considered injectable therapy to be more effective than other medication. 
In addition, the majority of the sample (70%) felt better supported in their illness by virtue of 
regular contact with the doctor or nurse who administered their injection. Patients also reported 
that injectable treatment could impact positively on their plans and aspirations, with the most 
frequent consideration for the future relating to finding a job (49% of the sample).
Conclusion: In this survey, patients with schizophrenia had favorable opinions on injectable 
medication. Ultimately, positive experiences associated with the treatment of schizophrenia 
in patients receiving long-acting injectable medication may influence the p  rescription of such 
therapy by health care providers.
Keywords: schizophrenia, patient opinion, antipsychotic agents, depot preparations, dosage 
forms, injections
Introduction
When patients receive treatment for schizophrenia, long-acting injectable forms of 
typical antipsychotic medication are an option that has been used to ensure compliance 
with maintenance therapy.1 However, treatment with typical medication often produces 
side effects, including weight gain, sedation, hypotension, seizures, acute extrapyramidal 
symptoms (eg, parkinsonism, akathisia, and dystonia), and chronic motor problems (eg, 
tardive dyskinesia, chronic akathisia, and tardive dystonia).2,3 Consequently, although 
injecting such drugs (which are also available in tablet or liquid form) may be regarded 
as convenient from the perspective of the health care provider, patients may require 
coercing to accept them. Indeed, coercion has been highlighted as a conceptual issue in 
a consideration of the ethical use of medication in the treatment of severe and   persistent Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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mental illness,4 and health care providers may have negative 
attitudes towards injectable antipsychotic medication.5,6
New-generation, atypical antipsychotic therapies have 
become available. Results from long-term clinical studies 
have suggested that atypical medication may have a  dvantages 
over orally administered typical drugs, with patients having 
fewer relapses, more effective symptom control, and a lower 
incidence of movement disorders, although weight gain 
may be an issue.7 The clinical advantage of oral atypical 
a  ntipsychotic agents may be limited by compliance, and long-
acting preparations of these drugs can afford the opportunity 
to achieve consistent and sustained drug coverage.7 Thus, 
attention should be given to injectable depot antipsychotic 
therapy, which, with the advent of atypical preparations, may 
help to address compliance issues.
Given the potential benefits of the new generation of 
antipsychotic drugs, it is valuable to determine patients’ 
c  urrent opinions towards the prescription of long-acting 
injectable medication, and the nature of the relationships 
between patients and health care providers. Patient-reported 
outcomes are being used increasingly to assess the care of 
individuals with schizophrenia,8 and we describe a survey 
designed to evaluate patient opinion on long-acting intramus-
cular antipsychotic medication. The survey, which involved 
patients regardless of whether they were receiving typical or 
atypical drugs, also considered broader issues, ie, patients’ 
perception of their illness, information received in relation 
to schizophrenia, and other forms of prescribed m  edication. 
Ultimately, adding to this body of knowledge may influence 
health care providers when considering the prescription of 
long-acting injectable antipsychotic   medication for patients 
with schizophrenia.
Methods
survey
The content, wording, and order of the questions in the survey 
were developed by a scientific steering committee (details 
of which are given in the Acknowledgments). The questions 
were subsequently approved by the Union Nationale des 
Amis et Familles des Malades Mentaux (the National Union 
of Friends and Families of Mental Health Patients) and 
the Fédération Nationale des Associations d’Usagers en 
Psychiatrie (National Federation of Associations of Users in 
Psychiatry). After initially piloting the survey in 14 patients, 
a slightly amended version was validated by BVA, a market 
and opinion research agency (Boulogne-Billancourt, France), 
which specializes in opinion and health care, and respecting 
appropriate ethical standards.
The questions covered three areas, ie, patients’ perception 
of their illness and the information they had received in 
relation to schizophrenia, the various forms of treatment the 
patients had received, and specific issues relating to injectable 
treatment (Table 1). Some of the questions required answers 
to be selected from multiple-choice options, whereas others 
were open-ended.
sampling
The survey was conducted in outpatient clinics and day care cen-
ters throughout France, with potential sites and physicians being 
identified by Janssen Cilag, France. Psychiatrists who agreed 
to participate selected appropriate patients with schizophrenia 
who might wish to be included in the survey. To be e  ligible to 
participate, patients should have received at least three months’ 
treatment with a long-acting injectable antipsychotic (either 
typical or atypical) on an outpatient basis (attending hospitals or 
day care centers), with the psychiatrist considering their condi-
tion to have remained stable during this time. All patients were 
required to provide informed consent. Patients whose condition 
was not judged to be sufficiently stable were excluded, as were 
individuals who did not provide consent.
interviews
Interviews were conducted by 11 professional interviewers 
from the BVA agency who were experienced in the field 
of behavioral health. The interviews took place after the 
patients’ consent had been obtained, and in accordance with 
the availability of the patients and their professional health 
care providers. The majority of interviews were held during an 
outpatient consultation or in a day care center. The i  nterviews 
generally lasted around 15 minutes, with patients being asked 
each question as appropriate (ie, some items were filtered 
according to patients’ responses). I  nterviewers met patients 
face-to-face, and health care p  roviders were not present 
during the interview. Anonymized written records of the 
interviews were produced.
Data analysis
No formal sample size calculation was performed. However, 
a sample of 200 patients was targeted, from which it was 
estimated that approximately 20 psychiatrists could each 
enroll around 10 patients. Data were analyzed for the entire 
sample of patients who participated in the survey. Answers 
to multiple-choice questions were expressed in terms of 
the p  ercentage of patients giving a particular response. 
For open-ended q  uestions, the most frequently cited responses 
were c  ategorized and quantified accordingly.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 1 Questions included in the survey
Patients’ perception of their illness and information received in relation to schizophrenia
Do you feel ill?
Do you know the name of the illness you have? if so, what is it? (spontaneous answer)
Who informed you that you were ill? (spontaneous answer)
since you became ill, who has most regularly provided you with information about your illness? (spontaneous answer)
When someone talked to you about your illness for the first time, did he or she give you any information or an explanation about treatment for the illness?
since you were informed you were ill:
  have the medical staff been listening to you?
  have the medical staff answered all your questions?
  has the information you have received been clear?
  Has the information you have received been sufficient?
Forms of treatment administered to the patients
since you became ill, which of the following treatments have you used?
  injections
  Tablets taken with water
  Drinkable solution (drops)
  Tablets that melt in the mouth
For patients who had received at least two forms of medication:
Of those treatments you have used, which do you prefer?
For patients who preferred injections:
Please give the reason for your preference (spontaneous answer)
For patients who preferred tablets:
Please give the reason for your preference (spontaneous answer)
Injectable treatment
Do you know why this injectable treatment was prescribed for you? (spontaneous answer)
Did the doctor who prescribed this injectable treatment for you talk about the following?
  The place where you can inject yourself
  The frequency of the injections
  The advantages of this injectable treatment over other treatments
  Possible undesirable effects of this treatment
how do you feel today after having received an injectable treatment?
For patients who felt better than before:
What for you are the main advantages of your injectable treatment? (spontaneous answer)
i am going to quote you various opinions. Please tell me if they correspond quite closely or quite poorly to your feelings about your treatment:
  injectable treatment is more effective against my symptoms and my illness than tablets (or a drinkable solution).
  injectable treatment has fewer undesirable effects than tablets (or a drinkable solution).
  either a nurse or a doctor gives me my injection, so i feel better supported in my illness.
have you ever skipped an injection on purpose without having talked about it beforehand with a doctor?
Does the injectable treatment that you are now receiving allow you to envision your plans and aspirations more optimistically?
What are your current plans and aspirations? (spontaneous answer)
Notes: The questions listed above are generally shown according to their presentation in this article, which is not necessarily indicative of the order in which they were 
asked in the survey. Whereas some of the questions required answers to be selected from multiple-choice options, others were open-ended, with spontaneous answers 
being obtained as shown above.
Because patients were not asked to provide any details 
as to the specific treatments they were receiving (they were 
only questioned as to the way in which the medication was 
administered, eg, injectable, oral tablets), the results do not 
differentiate between typical and atypical drugs.
Results
Patients
A total of 206 patients from 19 sites throughout France 
were interviewed between May 2007 and July 2007. These 
patients had been under the care of a psychiatrist for a 
mean (± standard deviation) of 12 (±10) years. Baseline 
characteristics of the interviewees are shown in Table 2. 
The majority of patients interviewed were male and not 
engaged in any o  ccupational, educational, or voluntary 
activity.
Patients’ perception of illness  
and information received on schizophrenia
Thirty-nine percent of the patients interviewed did not 
feel that they were ill, and a minority (28%) of the sample 
knew they had a diagnosis of schizophrenia. Indeed, the 
name of their disease was unknown to 37% of the patients 
surveyed, whilst 35% of the sample believed their illness to Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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be a condition other than schizophrenia (mainly depression, 
psychological problems, or bipolar disorder).
The majority of patients had been informed of their 
  illness by a psychiatrist (59%) or general practitioner 
(23%), and most (91%) of the sample had also received 
i  nformation about their condition; this information was 
generally   provided by a psychiatrist (85%) or nurse (29%), 
and only 1% of patients reported self-instigated searches/
use of the Internet. Thirty-two percent of patients claimed 
to have received no information about the condition or its 
treatment at the time of diagnosis. When information was 
given to patients, this was generally received positively, 
with the majority of the sample considering that medical 
staff had listened to them and answered all their questions 
(89% and 81% respondents, respectively). However, there 
remained a requirement for patients to be given information 
that was more complete and more clear.
Forms of treatment administered  
to patients
Patients had received a mean of three different forms of 
treatment. All had received an injectable drug, because this 
was a requirement for inclusion in the survey, and 95% of the 
sample had been treated with more than one form of medica-
tion. Oral tablets (to be taken with water), drinkable solutions, 
and orally disintegrating tablets had also been prescribed (for 
94%, 52%, and 28% of patients, respectively). In patients 
who had received therapy with at least two forms of medica-
tion, injections were the favored dosage form, being preferred 
by 47% of the sample (Table 3). The most frequently given 
reasons for patients preferring injections were that the doses 
were spread out over time (41% of patients in whom this 
was the favored treatment modality), and there was no risk 
of forgetting a dose (39%). In those patients who preferred 
tablets to be taken with water, the most frequently stated 
basis for this was a dislike of injections (32%). Responses 
from the survey suggested that patients often had a favorable 
opinion of injectable medication, and this form of treatment 
was subsequently considered in more detail.
injectable treatment
The most common reasons cited by patients as the grounds 
for which their injectable treatment had been prescribed 
were the constraints, or lack of effectiveness, of previous 
therapy (40% and 39%, respectively). When the injections 
were instigated, the majority of the information about the 
treatment given to the patients by physicians was concerned 
with practical details of the injection procedure (injection 
site [described to 97% of the sample] and injection frequency 
[described to 93% of the sample]). Less information was 
described in relation to the advantages and possible side 
effects of the injectable treatment, with 37% of patients 
unable to recall being given any details of these two aspects 
of the therapy. This group of patients comprised mainly 
those who were unaware of the reason for their being pre-
scribed the injectable treatment (66%) or the reason for their 
being followed-up (47%), and individuals over 50 years of 
age (51%).
Over two-thirds of the sample (67%) said they felt b  etter 
having received an injectable treatment than they did before 
(Table 4), and over half the patients (51%) considered 
the injectable treatment to be more effective than other 
medication. Patients who felt better than before reported the 
f  ollowing main advantages of injectable treatment: fe  eling 
Table  4  Patients’  feelings  after  having  received  an  injectable 
treatment (n = 206)
Description Percentage of patients
Better than before 67
neither better nor worse 23
not as well as before 8
Patients did not know 2
Table 2 Baseline characteristics of the patients surveyed (n = 206)
Characteristic Percentage of patients
gender
Male 65
Female 35
Age (years)
,35 29
35–49 48
$50 23
Living arrangement
Alone 43
With family 38
With partner 10
social institution 8
engagement in occupational, educational,  
or voluntary activity
13
engagement in leisure activity 51a
Note: aOf whom 16% belonged to a club or self-help group.
Table 3 Preferred treatment as described by patients who had 
used at least two forms (n = 196)
Description Percentage of patients
injections 47
Tablets taken with water 35
Drinkable solutions 7
Orally disintegrating tablets 1
Patients did not know 10Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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less anxious, calmer (67%); feeling less depressed or   having 
a better mood (30%); feeling more resilient/energetic (24%); 
having fewer hallucinations (15%); and being more sociable/
having friends (11%). In addition to such benefits, the major-
ity of the sample (70%) felt better supported in their illness 
by virtue of regular contact with the doctor or nurse who 
administered their injection. Indeed, 88% of patients had never 
deliberately missed an injection without having discussed this 
beforehand with their doctor.
Injectable treatment may also impact positively on 
patients’ plans and aspirations; 47% of the sample reported 
that the therapy allowed them to view their plans and aspira-
tions more optimistically. The most frequent considerations 
for the future related to finding a job (49% of the sample) and 
concerns for social and family lives (22%). Other aspirations 
related to leisure activity (19%), greater autonomy (17%), 
and cure (10%).
No differences with regard to undesirable side effects 
were apparent between injectable medication and   treatments 
administered via an oral route. When presented with the 
s  tatement “Injectable medication has fewer undesirable effects 
than tablets (or a drinkable solution)”, 30% of respondents 
reported this to correspond closely with their feelings, 30% 
reported a poor correspondence, and 40% did not know.
Discussion
Injections were the form of antipsychotic medication pre-
ferred by most of the patients in our survey. However, this 
study had its limitations, in that all the interviewees were 
receiving long-acting injectable drugs, and the results were 
obtained from a relatively small sample of patients, recruited 
over a short period of time. This may raise a question as to the 
degree to which our findings can be extended to other patients 
with schizophrenia. However, in this context, it is appropriate 
to note that, as described below, patients r  eporting a favorable 
perception towards injectable antipsychotic medication is in 
line with other published findings.
Although few data have described the subjective 
experiences of people who receive depot injections in the 
community,9 the data that are available, although of variable 
quality, generally show patients to be positive in their percep-
tion of injectable antipsychotic medication. Two previously 
published reviews10,11 identified 12 studies describing specific 
attitudinal or preferential data.12–23 Ten of these studies, all 
of which were cross-sectional surveys, conveyed positive 
opinions of depot medication.12,14–18,20–23 Six of the 12 studies 
identified in the reviews directly compared patient prefer-
ences for depot and oral treatments.13,14,16,17,20,23 In five of 
these six studies, depot medication was preferred by more 
patients.14,16,17,20,23
Hovens et al24 have subsequently reported that patients 
with schizophrenia prefer long-acting injections, d  escribing 
the results of semistructured interviews performed with 
92 outpatients who were receiving antipsychotic medication. 
The patients in this sample considered long-acting injections 
to offer the most advantages and the fewest disadvantages 
of all methods of administration of antipsychotic drugs, 
re  gardless of the treatment they were receiving (conventional 
oral medication, atypical oral medication, conventional long-
acting injections, or atypical long-acting injections) when 
they expressed this opinion.
In a recent survey of 300 patients shortly before discharge 
from a psychiatric hospital, Heres et al25 found the preference 
for depots as favorable antipsychotic medication to depend on 
patients’ experience with the formulation, and a considerable 
number of patients were willing to accept a depot drug for 
long-term treatment.
However, despite patients’ generally favorable perception 
of injectable antipsychotic medication, as described in 
the results earlier, practicing psychiatrists and nurses may 
be surprised that patients prefer injections. Health care 
p  roviders’ perception of patients’ overall experience of such 
therapy may be influenced by experience of administering 
injections, because the injection procedure itself may not 
be particularly agreeable for the health care provider or for 
the patient. In addition, health care providers may consider 
i  njections as a means of maintaining control over drug 
administration. Indeed, previous reports have shown that 
psychiatrists and nurses may have negative attitudes towards 
long-acting injections.5,6 When depot medication is not pre-
scribed for patients, the reasons given for not prescribing this 
treatment may not be supported by available evidence.26
In our survey, 67% of patients claimed to feel better 
having received an injected drug. This might be expected, 
given the benefits of effective long-term maintenance 
therapy in schizophrenia, the relative convenience of the 
treatment (preclusion of the requirement to take medication 
daily), and the support provided through regular contact 
with health care providers when patients attend appoint-
ments to receive injections. Indeed, 70% of our sample said 
that they felt b  etter supported in their illness; in addition to 
  assistance, health care providers can offer reassurance, help-
ing patients in their decision to receive medication. The time 
that nurses spend with patients at clinics when injections are 
administered can enable relationships to develop that extend 
beyond merely the provision of a biological intervention Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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in schizophrenia, providing a forum enabling patients to 
  discuss both clinical and   psychosocial issues relating to their 
  condition.9 This may contrast with the situation for patients 
with schizophrenia prescribed oral drugs, who have to make 
decisions to comply with treatment on a daily basis, ie, deci-
sions that may be made alone and can be adversely influenced 
if patients do not believe themselves to be ill.
Our results raise several other interesting points in 
r  elation to patients’ perception of schizophrenia and the man-
ner in which they are treated. Whilst a minority (28%) of the 
sample were aware that they had schizophrenia, this does not 
necessarily indicate that the patients did not understand the 
symptoms and problems associated with the disease. Indeed, 
previous data have confirmed that patients can understand 
the nature of their illness.27 However, it is possible that, in 
some instances, a diagnosis of schizophrenia may not have 
been specified to avoid labeling a patient. Rather than reduce 
discussion to a dialog focused exclusively on the diagnosis, 
the health care providers involved may have attached more 
importance to providing support, and helping patients to 
recognize and deal with problems they are liable to experi-
ence as a consequence of having the condition.
That information about schizophrenia was generally 
provided to patients by a psychiatrist (85% of the sample) 
or nurse (29% of the sample) demonstrates links in the team 
providing health care, and such links can help to facilitate 
the provision of effective treatment and patient support. 
In relation to this, the importance of postdiagnostic education 
should be emphasized, because the knowledge gained will 
help patients to understand better the nature of their condi-
tion and the means of treating it. Well-informed patients are 
likely to be more receptive to treatment and to acknowledge 
its benefits, and transparency of information given to patients 
by health care providers is likely to produce greater accept-
ability of therapy.
Patients with schizophrenia may wish to be involved 
in decisions about their treatment.28 Rather than being 
coerced into receiving injections, patients should be 
actively involved in their own care, and the provision of 
c  omprehensive i  nformation may help patients to decide to 
attend clinics where they can be given appropriate treatment. 
E  ncouragingly, most patients in the sample found medical 
staff responsive and ready to answer questions, reporting all 
their questions to be answered. However, the information 
provided to patients was not always regarded as sufficiently 
complete or clear enough. Whilst the survey found that 
patients tended to be well informed about practical details 
relating to the injectable medication, interviewees claimed 
to have received less information concerning the advantages 
and possible disadvantages of such treatment. This might, 
in part, reflect the attitudes of psychiatrists, who can find it 
more difficult to promote i  njections if they regard them as 
having d  isadvantages for patients, or being an obligation. 
The value of updating psychiatrists’ knowledge of depot 
medication, so as to promote a more positive attitude, has 
been highlighted in the literature.5,6
This survey showed that patients receiving injectable 
treatment reported subsequent positive effects on their 
aspirations, with treated patients making plans relating to 
assimilation into society, such as finding a job and   integrating 
into social and family life. Patients may realize that although 
they cannot be cured, they can still have ambitions for the 
future.
In conclusion, injectable medication was the dosage form 
preferred by most patients in this survey. This p  reference is 
in line with previously published results showing   positive 
patient attitudes towards injectable treatment, but may 
surprise practicing psychiatrists and nurses. Patients in this 
survey claimed to feel better having received an injected 
drug, and said that they felt better supported in their illness. 
They also reported that injectable medication could allow 
them to view their plans and aspirations more optimistically. 
Patients rated health care providers positively, g  enerally 
finding them willing to provide information, s  upport, and 
r  eassurance. Ultimately, more positive experiences a  ssociated 
with the treatment of schizophrenia in patients receiving long-
acting injectable medication may influence the prescription 
of such therapy by health care providers.
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